Entero Healthcare Solutions Ltd (ENTERO)
₹1,229.60
Mkt cap
₹5,352 Cr
P/E ratio
44.80
P/B
3.17
Div yield
0.00%
ROE
6.99%
ROCE
10.60%
EPS (TTM)
₹27.45
Book value
₹388
52W range
949–1,354
Sector
Consumer Discretionary
Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services [1]
Health check
Constructive
ValuationFair
ProfitabilityWeak
GrowthHigh
TechnicalsBullish
52-week range
−9.21% from high₹1,230
₹949+29.54% from low₹1,354
Current
₹1,229.60
Prev close
₹1,230.00
Day
−0.03%
Price performance
1D
−0.03%
1W
+3.35%
1M
+4.17%
3M
−1.64%
6M
+7.45%
1Y
+3.53%
YTD
+9.44%
Financials
FRevenue, profit & margin
P/E ratio
44.8×
ENTERO is 4% above the sector median of 43.0×
ENTERO44.8×
Sector median43.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 887 | 899 | 996 | 993 | 1,034 | 1,097 | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 | 1,707 | 1,910 | |
| Expenses | 867 | 873 | 968 | 964 | 1,005 | 1,067 | 1,258 | 1,309 | 1,290 | 1,354 | 1,509 | 1,639 | 1,824 | |
| Operating Profit | 20 | 26 | 29 | 29 | 29 | 30 | 42 | 50 | 49 | 50 | 62 | 68 | 86 | |
| OPM % | 2% | 3% | 3% | 3% | 3% | 3% | 3% | 4% | 4% | 4% | 4% | 4% | 4% | |
| Other Income | 1 | 1 | 2 | 2 | 9 | 13 | 11 | 8 | 7 | 6 | 5 | -4 | 4 | |
| Interest | 13 | 14 | 18 | 16 | 17 | 10 | 11 | 10 | 10 | 11 | 12 | 14 | 17 | |
| Depreciation | 7 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 10 | 10 | 15 | |
| Profit before tax | 1 | 7 | 7 | 8 | 14 | 27 | 35 | 39 | 37 | 36 | 45 | 40 | 58 | |
| Tax % | 490% | 6% | 23% | 16% | -56% | 25% | 25% | 25% | 16% | 17% | 18% | 16% | 22% | |
| Net Profit | -4 | 6 | 5 | 7 | 21 | 21 | 26 | 29 | 31 | 30 | 37 | 34 | 45 | |
| EPS in Rs | -9.05 | 15.18 | 3.19 | 4.22 | 4.82 | 4.62 | 5.43 | 5.85 | 5.90 | 6.39 | 7.26 | 6.35 | 6.44 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202652.40%Promoter
Promoters52.40%0.02
FIIs4.36%0.33
DIIs15.48%1.14
Public27.77%0.83
Ownership trend
Peers
P2 companies| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Medplus Health | ₹720.55 | 41.13 | 8,656 | 0.00% | 33 | −21.67% | 1,880 | +21.84% | 12.65% |
| Entero Healthcar | ₹1,229.60 | 44.84 | 5,352 | 0.00% | 45 | +9.03% | 1,910 | +42.63% | 10.55% |
| Median: 2 Co. | ₹975.07 | 42.98 | 7,004 | 0.00% | 39 | −6.32% | 1,895 | +32.23% | 11.60% |
Filings
DAnnual reports2
Concall transcripts26
TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJun 2024PPTJun 2024RECJun 2024PPTMay 2024
Credit ratings3
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 1d - News paper advertisement - 8th Annual General Meeting through Video conferencing / Other Audio - Visual Means (VC/OAVM) facility.Announcement under Regulation 30 (LODR)-Change in Management 13 Jul - Rajesh Dalal will not seek reappointment; ceases as Independent Director on August 24, 2026.Announcement under Regulation 30 (LODR)-Cessation 13 Jul - Rajesh Shashikant Dalal will cease as independent director and committee chair on August 24, 2026.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Jul - Certificate u/r 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026Announcement under Regulation 30 (LODR)-Change in Management 26 Jun - Board approved 1,475 ESOP shares and revised independent director reappointments from August 25, 2026.